Loading stock data…
ANVS
$2.22-0.06 (-2.63%)
Pre-Market$2.20-0.02 (-0.90%)· Last close May 13
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Annovis Bio, Inc. in the Healthcare sector is trading at $2.22. Wall Street consensus targets $12.50 (2 analysts), implying a +463.1% move over the next 12 months. The stock is currently near its 52-week low of $1.54, remaining 16.2% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +463.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$2.22
Potential Downside
0%
Whystock Fair Value$2.22
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 t...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$63.54M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.36
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-167.04%
Volume
Today's trading volume
645,575
Recent News
Annovis (ANVS) Secures Patent Coverage for Both Forms of Buntanetap
Annovis Bio, Inc. (NYSE:ANVS) is one of the best meme stocks. On August 7, Annovis announced that it has finished transferring patents for both the older semi-crystalline and the newer crystalline versions of its drug candidate, buntanetap. These patents will now protect the drug until 2046. The company, which works on drugs for brain-related diseases, […]
We Think Annovis Bio (NYSE:ANVS) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
All You Need to Know About Annovis Bio (ANVS) Rating Upgrade to Buy
Annovis Bio (ANVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.